Completed
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
NCT00856908
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +4 more
- Locations
-
- Research Site Chula Vista, California, United States